Hydrolysis, Ligand Exchange, and Redox Properties of Vanadium Compounds: Implications of Solution Transformation on Biological, Therapeutic, and Environmental …
Vanadium is a transition metal with important industrial, technological, biological, and
biomedical applications widespread in the environment and in living beings. The different …
biomedical applications widespread in the environment and in living beings. The different …
Anticancer perspectives of vanadium complexes
Vanadium metal is widely spread in various environments and has essential roles in
biological systems. Vanadium based compounds have been proposed for cancer as a new …
biological systems. Vanadium based compounds have been proposed for cancer as a new …
Vanadium (IV) complexes of salicylaldehyde-based furoic acid hydrazones: Synthesis, BSA binding and in vivo antidiabetic potential
Solution synthesis afforded five novel neutral heteroleptic octahedral paramagnetic
mononuclear oxidovanadium (IV) complexes of general composition [VO (bpy) L], where L is …
mononuclear oxidovanadium (IV) complexes of general composition [VO (bpy) L], where L is …
Water-soluble dioxidovanadium (V) complexes of aroylhydrazones: DNA/BSA interactions, hydrophobicity, and cell-selective anticancer potential
Five new anionic aqueous dioxidovanadium (V) complexes,[{VO2L1, 2} A (H2O) n] α (1–5),
with the aroylhydrazone ligands pyridine-4-carboxylic acid (3-ethoxy-2-hydroxybenzylidene) …
with the aroylhydrazone ligands pyridine-4-carboxylic acid (3-ethoxy-2-hydroxybenzylidene) …
Ruthenium (II)‐Dithiocarbazates as Anticancer Agents: Synthesis, Solution Behavior, and Mitochondria‐Targeted Apoptotic Cell Death
The reaction of the Ru (PPh3) 3Cl2 with HL1− 3− OH (− OH stands for the oxime hydroxyl
group; HL1− OH= diacetylmonoxime‐S‐benzyldithiocarbazonate; HL2− OH …
group; HL1− OH= diacetylmonoxime‐S‐benzyldithiocarbazonate; HL2− OH …
LVVO-Ethyl Maltol-Based Metallodrugs (L2– = Tridentate ONO Ligands): Hydrophobicity, Hydrolytic Stability, and Cytotoxicity via ROS-Mediated Apoptosis
Four new oxidovanadium [VVOL1–4 (ema)] complexes (1–4) have been synthesized using
tridentate binegative ONO donor ligands H2L1–4 [H2L1:(E)-N′-(2-hydroxybenzylidene) …
tridentate binegative ONO donor ligands H2L1–4 [H2L1:(E)-N′-(2-hydroxybenzylidene) …
Fluorescent Diorganotin (IV) Complexes as Anticancer Agents: Study of Cytotoxicity, Cellular Localization, and Mechanism of Cell Death
Three luminescent mixed ligand diorganotin (IV) complexes [Sn2Ph4 (L) 1–3 (DPA)(MeOH)
Cl](where L1=(Z)-N-((E)-3-ethoxy-2-hydroxybenzylidene) isonicotinohydrazonic acid, L2=(Z) …
Cl](where L1=(Z)-N-((E)-3-ethoxy-2-hydroxybenzylidene) isonicotinohydrazonic acid, L2=(Z) …
Evaluation of DNA/BSA interaction and in vitro cell cytotoxicity of μ2-oxido bridged divanadium (V) complexes containing ONO donor ligands
Two new μ 2-oxido bridged divanadium (V) complexes,[VV 2 O 3 (L 1, 2) 2](1 and 2) have
been synthesized using bi-negative tridentate ONO-donor ligands, H 2 L 1, 2 (H 2 L 1= 4-tert …
been synthesized using bi-negative tridentate ONO-donor ligands, H 2 L 1, 2 (H 2 L 1= 4-tert …
Interaction with bioligands and in vitro cytotoxicity of a new dinuclear dioxido vanadium (V) complex
BK Biswas, N Biswas, S Saha, A Rahaman… - Journal of Inorganic …, 2022 - Elsevier
One centrosymmetric bis (μ-oxido)-bridged vanadium (V) dimer with molecular formula
[(VVO 2) 2 (pedf) 2](1) has been synthesized from the reaction of VOSO 4· 5H 2 O with a …
[(VVO 2) 2 (pedf) 2](1) has been synthesized from the reaction of VOSO 4· 5H 2 O with a …
Brief research on the biophysical study and anticancer behavior of Pt (II) complexes: their DNA/BSA binding, molecular docking, and cytotoxic property
The potent bidentate carrier ligand 2-picolylamine (pic) has been used to synthesize Pt (II)
complexes to know their bioactivity and anticancer property as reflected by PASS prediction …
complexes to know their bioactivity and anticancer property as reflected by PASS prediction …